164 related articles for article (PubMed ID: 35520441)
1. Controlled delivery of a protein tyrosine phosphatase inhibitor, SHP099, using cyclodextrin-mediated host-guest interactions in polyelectrolyte multilayer films for cancer therapy.
Wang S; Battigelli A; Alkekhia D; Fairman A; Antoci V; Yang W; Moore D; Shukla A
RSC Adv; 2020 May; 10(34):20073-20082. PubMed ID: 35520441
[TBL] [Abstract][Full Text] [Related]
2. SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade.
Zhao M; Guo W; Wu Y; Yang C; Zhong L; Deng G; Zhu Y; Liu W; Gu Y; Lu Y; Kong L; Meng X; Xu Q; Sun Y
Acta Pharm Sin B; 2019 Mar; 9(2):304-315. PubMed ID: 30972278
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of the injectable thermosensitive hydrogel loaded with SHP099 on intervertebral disc degeneration.
Wang J; Huang L; Huang Y; Jiang Y; Zhang L; Feng G; Liu L
Life Sci; 2021 Feb; 266():118891. PubMed ID: 33310047
[TBL] [Abstract][Full Text] [Related]
4. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
[TBL] [Abstract][Full Text] [Related]
5. Probing the acting mode and advantages of RMC-4550 as an Src-homology 2 domain-containing protein tyrosine phosphatase (SHP2) inhibitor at molecular level through molecular docking and molecular dynamics.
Wang RR; Liu WS; Zhou L; Ma Y; Wang RL
J Biomol Struct Dyn; 2020 Mar; 38(5):1525-1538. PubMed ID: 31043123
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
7. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
[TBL] [Abstract][Full Text] [Related]
8. Cucurbit[8]uril-Containing Multilayer Films for the Photocontrolled Binding and Release of a Guest Molecule.
Nicolas H; Yuan B; Zhang X; Schönhoff M
Langmuir; 2016 Mar; 32(10):2410-8. PubMed ID: 26891704
[TBL] [Abstract][Full Text] [Related]
9. Role of SHP2 (PTPN11) in glycoprotein VI-dependent thrombus formation: Improved platelet responsiveness by the allosteric drug SHP099 in Noonan syndrome patients.
Fernández DI; Diender M; Hermida-Nogueira L; Huang J; Veiras S; Henskens YMC; Te Loo MWM; Heemskerk JWM; Kuijpers MJE; García Á
Thromb Res; 2023 Aug; 228():105-116. PubMed ID: 37302266
[TBL] [Abstract][Full Text] [Related]
10. Bioinspired Titanium Drug Eluting Platforms Based on a Poly-β-cyclodextrin-Chitosan Layer-by-Layer Self-Assembly Targeting Infections.
Pérez-Anes A; Gargouri M; Laure W; Van Den Berghe H; Courcot E; Sobocinski J; Tabary N; Chai F; Blach JF; Addad A; Woisel P; Douroumis D; Martel B; Blanchemain N; Lyskawa J
ACS Appl Mater Interfaces; 2015 Jun; 7(23):12882-93. PubMed ID: 25992843
[TBL] [Abstract][Full Text] [Related]
11. Intraarticular injection of SHP2 inhibitor SHP099 promotes the repair of rabbit full-thickness cartilage defect.
Sun Z; Xu X; Lv Z; Li J; Shi T; Sun H; Sun K; Tan G; Yan W; Yang YX; Wu R; Xu J; Guo H; Jiang Q; Shi D
J Orthop Translat; 2022 Jan; 32():112-120. PubMed ID: 35228993
[TBL] [Abstract][Full Text] [Related]
12. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SHP2 by the Small Molecule Drug SHP099 Prevents Lipopolysaccharide-Induced Acute Lung Injury in Mice.
Ye S; Zuo B; Xu L; Wu Y; Luo R; Ma L; Yao W; Chen L; Liang G; Zhang Y
Inflammation; 2023 Jun; 46(3):975-986. PubMed ID: 36732395
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Adoptive Cell Therapy by T Cell Loading of SHP2 Inhibitor Nanocrystals before Infusion.
Li X; Halldórsdóttir HR; Weller S; Colliander A; Bak M; Kempen P; Clergeaud G; Andresen TL
ACS Nano; 2022 Jul; 16(7):10918-10930. PubMed ID: 35838499
[TBL] [Abstract][Full Text] [Related]
15. Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Leung CON; Tong M; Chung KPS; Zhou L; Che N; Tang KH; Ding J; Lau EYT; Ng IOL; Ma S; Lee TKW
Hepatology; 2020 Jul; 72(1):155-168. PubMed ID: 31610028
[TBL] [Abstract][Full Text] [Related]
16. Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX; Wang H; Liu C; Kovats S; Velazquez R; Lu H; Pant B; Shirley M; Meyer MJ; Pu M; Lim J; Fleming M; Alexander L; Farsidjani A; LaMarche MJ; Moody S; Silver SJ; Caponigro G; Stuart DD; Abrams TJ; Hammerman PS; Williams J; Engelman JA; Goldoni S; Mohseni M
Mol Cancer Ther; 2019 Dec; 18(12):2368-2380. PubMed ID: 31439712
[No Abstract] [Full Text] [Related]
17. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic Inhibition of SHP2 Blocks Both PI3K and MEK Signaling in Low-epiregulin HNSCC via GAB1.
Kurupi R; Floros KV; Jacob S; Chawla AT; Cai J; Hu B; Puchalapalli M; Coon CM; Khatri R; Crowther GS; Egan RK; Murchie E; Greninger P; Dalton KM; Ghotra MS; Boikos SA; Koblinski JE; Harada H; Sun Y; Morgan IM; Basu D; Dozmorov MG; Benes CH; Faber AC
Cancer Res Commun; 2022 Sep; 2(9):1061-1074. PubMed ID: 36506869
[TBL] [Abstract][Full Text] [Related]
19. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
20. Dual Stimuli-Responsive Supramolecular Self-Assemblies Based on the Host-Guest Interaction between β-Cyclodextrin and Azobenzene for Cellular Drug Release.
Zhang J; Zhou ZH; Li L; Luo YL; Xu F; Chen Y
Mol Pharm; 2020 Apr; 17(4):1100-1113. PubMed ID: 32125862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
